ABSTRACT
A 64-year-old woman underwent completion thyroidectomy with upper tracheal ring resection and right-sided neck dissection for papillary carcinoma of the thyroid infiltrating the trachea and was given I radioiodine treatment. Three years later, she presented with hemoptysis. On evaluation, she had increased serum thyroglobulin and negative iodine scan (TENIS). F-FDG PET/CT scan did not identify any site of disease. One year later, Ga-PSMA scan done revealed a moderate focal tracer-avid intratracheal soft tissue; biopsy revealed it to be metastatic papillary carcinoma of the thyroid. This case kindles the possibility of using Ga-PSMA PET/CT to reveal occult disease in cases of TENIS.
Subject(s)
Edetic Acid/analogs & derivatives , Iodine Radioisotopes , Oligopeptides , Positron Emission Tomography Computed Tomography , Thyroglobulin/blood , Thyroid Neoplasms/pathology , Tracheal Neoplasms/diagnostic imaging , Tracheal Neoplasms/secondary , Biopsy , Carcinoma, Papillary/blood , Carcinoma, Papillary/diagnostic imaging , Carcinoma, Papillary/pathology , Female , Fluorodeoxyglucose F18 , Gallium Isotopes , Gallium Radioisotopes , Humans , Middle Aged , Thyroid Neoplasms/blood , Thyroid Neoplasms/diagnostic imagingABSTRACT
BACKGROUND/OBJECTIVES: The objective of the study was to assess the role of variations in serum folate, vitamin B12, homocysteine and the presence of genetic polymorphisms as risk factors for congenital heart disease (CHD) in children. SUBJECTS/METHODS: A total of 32 children with CHD, and their mothers and 32 normal children and their mothers formed the study and control groups, respectively. Serum folate, vitamin B12 and homocysteine as well as genetic polymorphisms MTHFR C677âï¸T, MTHFR A1298âï¸C, MTR A2756âï¸G and MTRR A66âï¸G were assessed. RESULTS: Low serum folate and genetic polymorphisms MTHFR C677âï¸T and MTRR A66âï¸G among children and their mothers and high homocysteine among mothers were noted as risk factors for CHD (P<0.05). Vitamin B12 levels were normal and showed no association. Presence of MTHFR C677âï¸T and MTRR A66âï¸G, both concurrently among children as well as mothers and simultaneously among mother-child pairs, showed several fold increase in the risk for CHD. On multivariate analysis, the risk factors noted for CHD were presence of MTHFR C677âï¸T among children and their mothers and MTRR A66âï¸G among mothers. Analyses for nutrient-gene interaction revealed significant associations between low serum folate and high serum homocysteine levels, and the presence of selected genetic polymorphisms. CONCLUSIONS: Low serum folate, high homocysteine and presence of selected genetic polymorphisms among children and their mothers were noted as risk factors for CHD. Nutrient-gene interaction being a modifiable risk factor, the study recommends the use of peri-conceptional folate supplementation with vitamin B12 sufficiency for primary prevention of CHD.
Subject(s)
Ferredoxin-NADP Reductase/genetics , Folic Acid/blood , Heart Defects, Congenital/blood , Heart Defects, Congenital/genetics , Homocysteine/blood , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Vitamin B 12/blood , Adult , Case-Control Studies , Child , Child, Preschool , Gene-Environment Interaction , Genetic Predisposition to Disease , Humans , Infant , Mothers , Polymorphism, Single Nucleotide , Risk Factors , Socioeconomic Factors , Young AdultABSTRACT
A 66-year-old man on hormonal therapy with prostate cancer was referred for Ga-PSMA PET/CT scan for biochemical recurrence. Ga-PSMA PET/CT scan detected moderate heterogeneous tracer concentration in bilateral breast parenchyma, in addition to the abnormal tracer concentration in enlarged prostate gland, right external iliac lymph node, and sclerotic lesion in L4 vertebra. On clinical examination, he was found to have bilateral gynecomastia. Abnormal concentration of Ga-PSMA in breast cancer is now well known, and in this context, it is important to know that tracer localization can occur in gynecomastia as well, as evidenced in this case.
Subject(s)
Edetic Acid/analogs & derivatives , Gynecomastia/diagnostic imaging , Gynecomastia/metabolism , Oligopeptides/metabolism , Positron Emission Tomography Computed Tomography , Aged , Edetic Acid/metabolism , False Positive Reactions , Gallium Isotopes , Gallium Radioisotopes , Gynecomastia/pathology , Humans , Male , RecurrenceABSTRACT
Inheritance of genomic information independent of the DNA sequence, the epigenetics, as well as gene transcription are profoundly shaped by serine/threonine and tyrosine signaling kinases and components of the chromatin remodeling complexes. To precisely respond to a changing external milieu, human cells efficiently translate upstream signals into post-translational modifications (PTMs) on histones and coregulators such as corepressors, coactivators, DNA-binding factors and PTM modifying enzymes. Because a protein with multiple residues for putative PTMs is expected to undergo more than one PTM in cells stimulated with growth factors, the outcome of combinational PTM codes on histones and coregulators is profoundly shaped by regulatory interplays between PTMs. The genomic functions of signaling kinases in cancer cells are manifested by the downstream effectors of cytoplasmic signaling cascades as well as translocation of the cytoplasmic signaling kinases to the nucleus. Signaling-mediated phosphorylation of histones serves as a regulatory switch for other PTMs, and connects chromatin remodeling complexes into gene transcription and gene activity. Here, we will discuss the recent advances in signaling-dependent epigenomic regulation of gene transcription using a few representative cancer-relevant serine/threonine and tyrosine kinases and their interplay with chromatin remodeling factors in cancer cells.
Subject(s)
Epigenomics , Neoplasms/genetics , Protein Serine-Threonine Kinases/genetics , Protein-Tyrosine Kinases/genetics , Chromatin Assembly and Disassembly/genetics , Gene Expression Regulation, Neoplastic , Histones/genetics , Humans , Phosphorylation , Protein Processing, Post-Translational/genetics , Signal TransductionABSTRACT
Chromatin remodeling factor metastatic tumor protein 1 (MTA1), one of the most upregulated oncogene in human cancer, has an important role in gene expression, cell survival and promoting hypoxic response. Successful cancer progression is dependent on the ability of cells to utilize its survival pathways for adapting to hypoxic microenvironment. Although MTA1 is a stress-responsive gene, but whether hypoxia modulates its function and its role in engaging other core stress-responsive survival pathway(s) remains unknown. Here we have discovered that MTA1 is a novel corepressor of serum and glucocorticoid-inducible kinase 1 (SGK1). Surprisingly, this regulatory corepressive function of MTA1 is lost under hypoxia, allowing upregulation of SGK1 expression and engaging the MTA1-SGK1 axis for the benefit of the cell survival. The underlying mechanism of the noticed stimulation of SGK1 expression by hypoxia includes de-repression of SGK1 transcription because of hypoxia-triggered nucleus-to-cytoplasmic translocation of MTA1. In addition, the newly recognized cytoplasmic translocation of MTA1 was dependent on the chaperoning function of heat shock protein 90 (HSP90) and co-accompanied by the formation of MTA1, HSP90 and HIF1α complex under hypoxic condition but not under normoxic condition. Hypoxia-triggered redistribution of MTA1, SGK1 upregulation and cell survival functions were compromised by a pharmacological SGK1 inhibitor. In summary, for the first time, we report MTA1 regulation of SGK1 expression, hypoxia-dependent MTA1 translocation to the cytoplasm and de-repression of SGK1 transcription. These findings illustrate how cancer cells utilize a chromatin remodeling factor to engage a core survival pathway to support its cancerous phenotypes, and reveal new facets of MTA1-SGK1 axis by a physiologic signal in cancer progression.
Subject(s)
Cell Hypoxia/physiology , Histone Deacetylases/genetics , Histone Deacetylases/metabolism , Immediate-Early Proteins/genetics , Immediate-Early Proteins/metabolism , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cytoplasm/genetics , Cytoplasm/metabolism , Female , Humans , MCF-7 Cells , Mice, Knockout , Signal Transduction , Trans-Activators , TransfectionABSTRACT
A 48-year-old female presented with a pathological fracture of the right femur. 99mTc methylene diphosphonate bone scan revealed multiple areas of increased osteoblastic activity consistent with metastatic disease. Serum electrophoresis revealed monoclonal gammopathy. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan revealed metabolically active lesions in bulky uterine cervix and osteolytic skeletal lesions. Unusual pattern of FDG uptake in uterine cervix and osteolytic skeletal lesions warranted a biopsy of the uterine cervix which revealed diffuse large B-cell lymphoma. 18F-FDG PET/CT scan helped in guiding the site of biopsy to reach a final diagnosis in this unusual case of lymphoma with a secondary involvement of uterine cervix presenting as a pathological fracture.
ABSTRACT
Fibrous dysplasia (FD) is a benign bone lesion with a rare but potential for malignant transformation. Neither Tc-MDP nor F-FDG PET/CT can differentiate between FD and areas of malignant transformation in FD. We described a case of osteosarcoma developing in FD with selective uptake of tracer in malignant transformation areas demonstrated on a Ga-PSMA PET/CT scan. Our case highlights the ability of Ga-PSMA PET/CT to map tumor neoangiogenesis in osteosarcoma arising in FD, which can have potential implications in prognostication, possibility of antiangiogenesis-based therapeutic options, and in response assessment following chemotherapy.
Subject(s)
Bone Neoplasms/complications , Bone Neoplasms/diagnostic imaging , Edetic Acid/analogs & derivatives , Fibrous Dysplasia of Bone/complications , Oligopeptides , Osteosarcoma/complications , Osteosarcoma/diagnostic imaging , Positron Emission Tomography Computed Tomography , Bone Neoplasms/pathology , Female , Gallium Isotopes , Gallium Radioisotopes , Humans , Middle Aged , Osteosarcoma/pathologyABSTRACT
A 68-year-old man presented with right-side facial numbness. MRI showed an extra-axial mass infiltrating the right temporal bone. It was debulked surgically, and histopathology revealed metastatic adenocarcinoma. Ga PSMA PET/CT done in view of increased PSA levels and clinically suspicious hard lesion in prostate showed primary lesion in left side of prostate with metastases to the right temporal bone. Primary carcinoma of the prostate and metastases to the right temporal bone were proven histopathologically. Our case highlights the usefulness of Ga PSMA PET/CT in identifying the primary site in suspected prostate cancer and mapping the metastatic sites.
Subject(s)
Adenocarcinoma/diagnostic imaging , Hypesthesia/diagnostic imaging , Positron Emission Tomography Computed Tomography , Prostatic Neoplasms/diagnostic imaging , Adenocarcinoma/pathology , Aged , Chin/diagnostic imaging , Chin/pathology , Diagnosis, Differential , Edetic Acid/analogs & derivatives , Gallium Isotopes , Gallium Radioisotopes , Humans , Hypesthesia/pathology , Male , Neoplasm Metastasis , Oligopeptides , Organometallic Compounds , Prostatic Neoplasms/pathology , RadiopharmaceuticalsABSTRACT
OBJECTIVE: To evaluate the feasibility of using Ga PSMA-11 PET/CT for imaging brain lesions and its comparison with F-FDG. METHODS: Ten patients with brain lesions were included in the study. Five patients were treated cases of glioblastoma with suspected recurrence. F-FDG and Ga PSMA-11 brain scans were done for these patients. Five patients were sent for assessing the nature (primary lesion/metastasis) of space occupying lesion in brain. They underwent whole body F-FDG PET/CT scan and a primary site elsewhere in the body was ruled out. Subsequently they underwent Ga PSMA-11 brain PET/CT imaging. Target to background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background. RESULTS: In five treated cases of glioblastoma with suspected recurrence the findings of Ga PSMA-11 PET/CT showed good correlation with that of F-FDG PET/CT scan. Compared to the F-FDG, Ga PSMA-11 PET/CT showed better visualization of the recurrent lesion (presence/absence) owing to its significantly high TBR. Among the five cases evaluated for lesion characterization glioma and atypical meningioma patients showed higher SUVmax in the lesion with Ga PSMA-11 than with F-FDG and converse in cases of lymphoma. TBR was better with Ga PSMA PET/CT in all cases. CONCLUSION: Ga PSMA-11 PET/CT brain imaging is a potentially useful imaging tool in the evaluation of brain lesions. Absence of physiological uptake of Ga PSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of metabolically active disease in brain.
Subject(s)
Brain Neoplasms/diagnostic imaging , Glioblastoma/diagnostic imaging , Lymphoma/diagnostic imaging , Meningeal Neoplasms/diagnostic imaging , Meningioma/diagnostic imaging , Neoplasm Recurrence, Local/diagnostic imaging , Adult , Aged , Child , Edetic Acid/analogs & derivatives , Female , Fluorodeoxyglucose F18 , Gallium Isotopes , Gallium Radioisotopes , Glioma/diagnostic imaging , Humans , Male , Middle Aged , Oligopeptides , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals , Whole Body Imaging , Young AdultSubject(s)
Edetic Acid/analogs & derivatives , Fluorodeoxyglucose F18 , Neoplasms, Multiple Primary/diagnostic imaging , Oligopeptides , Osteitis Deformans/diagnostic imaging , Prostatic Neoplasms/diagnostic imaging , Rectal Neoplasms/diagnostic imaging , Aged , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Diagnosis, Differential , Gallium Isotopes , Gallium Radioisotopes , Humans , Male , Multimodal Imaging/methods , Positron Emission Tomography Computed Tomography/methods , Radiopharmaceuticals , Rare Diseases/diagnostic imagingABSTRACT
We describe the case of a 55-year-old man who presented with history of fever for 3 months that began 2 months after he had undergone open reduction and internal fixation of left humerus fracture. Implant infection was suspected, but conventional imaging remained unyielding. Ga-DOTA ubiquicidin PET/CT showed increased tracer uptake along the entire length of the implant in the left humerus. Implant removal and temporary external fixation were done. In 24 hours, the patient became afebrile, and blood culture on the fourth day was sterile.
Subject(s)
Coordination Complexes/pharmacology , Peptides/pharmacology , Positron Emission Tomography Computed Tomography , Prosthesis-Related Infections/diagnostic imaging , Coordination Complexes/pharmacokinetics , Fractures, Bone/surgery , Gallium Radioisotopes , Humans , Male , Middle Aged , Peptides/pharmacokinetics , RadiopharmaceuticalsABSTRACT
The potential applications of Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in the imaging of prostate cancer are now well established. A few case reports regarding the potential use of Ga-PSMA PET/CT in nonprostate cancer malignancies are also published. Apparently, the tumor neoangiogenesis is the mechanism attributed to increased Ga-PSMA uptake in the tumor sites in nonprostatic malignancies. We describe the use of Ga-PSMA PET/CT in imaging multiple myeloma. The intense Ga-PSMA avidity of the lesions also opens up the possibility of theranostics with Lu-PSMA.
Subject(s)
Multiple Myeloma/diagnostic imaging , Organometallic Compounds , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals , Adult , Edetic Acid/analogs & derivatives , Gallium Isotopes , Gallium Radioisotopes , Humans , Male , OligopeptidesABSTRACT
65-year-old man with left-sided pelvic pain on evaluation was found to have features suggestive of either Paget disease or prostatic bone metastasis of the left hemipelvis based on Tc-MDP bone scan and MRI. Ga-PSMA PET/CT to assess the possibility of primary prostate cancer and if present to stage it helped to rule out prostate cancer because of absence of focal abnormal increased tracer uptake in the prostate gland. However, false-positive tracer uptake was noted in the left hemipelvis, which was subject to biopsy and histopathologically proven to be Paget disease involvement.
Subject(s)
Antigens, Surface/chemistry , Antigens, Surface/metabolism , Glutamate Carboxypeptidase II/chemistry , Glutamate Carboxypeptidase II/metabolism , Osteitis Deformans/diagnostic imaging , Osteitis Deformans/metabolism , Positron Emission Tomography Computed Tomography , Aged , Biological Transport , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Diagnosis, Differential , False Positive Reactions , Humans , Male , Prostatic Neoplasms/pathologyABSTRACT
INTRODUCTION: [(68)Ga]PSMA-11 is a relatively recently introduced radiopharmaceutical for PET-CT imaging of prostate cancer patients. The availability of (68)Ge/(68)Ga generator and PSMA-11 ligand from commercial sources is facilitating the production of the radiopharmaceutical in-house. This paper describes our experience on the preparation of ~200 batches of [(68)Ga]PSMA-11 for conducting PET-CT imaging in patients suspected/suffering from prostate cancer. METHODS: The radiosynthesis of [(68)Ga]PSMA-11 was done in a hospital based nuclear medicine department using (68)Ge/(68)Ga generator and a manual synthesis module, both supplied by Isotope Technologies Garching (ITG), Germany. The production involved the reaction of 5µg (5.3nmol) of PSMA-11 ligand in 1 ml of 0.25M sodium acetate buffer with 4ml of (68)GaCl3 in 0.05M HCl for 5min at 105°C; followed by purification in a C18 cartridge and collection through a 0.22µm pore size filter. RESULTS: The radiochemical yields obtained were consistently high, 93.19%±3.76%, and there was hardly any batch failure. The radiochemical purity of the product was >99% and the product was stable for over 2h; however it was used in patients immediately after preparation. About 200 batches of [(68)Ga]PSMA-11 were prepared during the period and more than 300 patients received the tracer during the 14months of study. No adverse reaction was observed in any of the patients and the image qualities were consistent with literature reports. CONCLUSION: [(68)Ga]PSMA-11 with high radiochemical and radionuclidic purity is conveniently prepared by using a (68)Ge/(68)Ga generator and manual synthesis module. The radiochemical yields are very high; and activity sufficient for 3-4 patients can be prepared in a single batch; multiple batches can be done on the same day and when needed after a gap of 1.5-2h.
Subject(s)
Gallium Radioisotopes/chemistry , Germanium/chemistry , Organometallic Compounds/chemical synthesis , Positron Emission Tomography Computed Tomography , Radiochemistry/methods , Chemistry Techniques, Synthetic , Drug Stability , Edetic Acid/analogs & derivatives , Gallium Isotopes , Oligopeptides , Organometallic Compounds/chemistry , Quality ControlABSTRACT
Ga-labeled prostate-specific membrane antigen (PSMA) is a potential tool in the imaging of recurrent prostate cancer. Ga-PSMA imaging is also useful for radiotherapy planning and in targeted therapy with Lu-PSMA. A few case reports regarding the use of Ga-PSMA in nonprostate cancer malignancies are also reported. We describe the use of Ga-PSMA imaging before Sm-EDTMP bone pain palliation therapy in a 58-year-old hormone refractory prostate cancer patient with extensive bone metastases.
Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Antigens, Surface , Bone Neoplasms/diagnostic imaging , Gallium Radioisotopes , Glutamate Carboxypeptidase II , Organometallic Compounds/therapeutic use , Organophosphorus Compounds/therapeutic use , Pain/drug therapy , Positron Emission Tomography Computed Tomography/methods , Bone Neoplasms/secondary , Gallium Radioisotopes/pharmacokinetics , Glutamate Carboxypeptidase II/pharmacokinetics , Humans , Male , Middle Aged , Palliative Care/methodsSubject(s)
Carcinoma, Hepatocellular/diagnostic imaging , Liver Neoplasms/diagnostic imaging , Multimodal Imaging , Organometallic Compounds , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed , Aged , Edetic Acid/analogs & derivatives , Gallium Isotopes , Gallium Radioisotopes , Humans , Male , OligopeptidesABSTRACT
177Lu-EDTMP has been proposed as a potent bone pain palliation agent owing to theoretical advantage of reduced bone marrow suppression resulting from the low ß(-) energy and a suitably long half-life facilitating its wider distribution with less loss from radioactive decay. Herein, we report the pharmacokinetics, dosimetry and toxicity analysis of 177Lu-EDTMP in patients (phase-0/I study). In a phase-0 study, the biokinetics of skeletal and non-skeletal uptake of 177Lu-EDTMP was assessed in 6 patients with metastatic prostate cancer using tracer doses (172.7-206.9MBq). Data of whole skeletal uptake, blood and fractionated urine samples were obtained and dosimetric calculations were performed using the OLINDA/EXM 1.0 software. Prolonged bone retention was observed in all patients. Excretion was mainly via the renal route and blood clearance was rapid and biphasic. Mean estimated red marrow dose was 0.80±0.15mGy/MBq while mean total-body dose was 0.16±0.04mGy/MBq. A maximum tolerated dose (MTD) of 2000-3250MBqfor 177Lu-EDTMP was calculated. For the phase-I study, 21 patients with metastatic prostate cancer were given a therapeutic dose of 177Lu- EDTMP (692-5550MBq). Toxiciy (WHO), evaluated by assessment of hemoglobin levels, platelet and leukocyte counts over 12 weeks, was mainly limited to anemia or thrombocytopenia. Only transient toxicity was observed in 14/21 patients, of which 6 had baseline toxicity. Beyond the MTD, a significantly higher number of patients displayed grade 3-4 toxicity. Pain relief, assessed by VAS pain score, was observed in 86% patients with median relief duration of 7 weeks. The results demonstrate that 177Lu-EDTMP has excellent pharmacokinetic and dosimetric properties, besides being safe and effective. Along with estimating radiation dose values to certain critical organs, we have also proposed an MTD for 177Lu-EDTMP that correlated well with toxicity data. The encouraging dosimetry and toxicity data of 177Lu-EDTMP reported provide the basis for subsequent phases of the studies to establish complete effectiveness and safety of 177Lu-EDTMP as an attractive alternative to other radioactive bone pain palliation agents.
Subject(s)
Bone Neoplasms/radiotherapy , Organometallic Compounds/administration & dosage , Organophosphorus Compounds/administration & dosage , Prostatic Neoplasms/radiotherapy , Radiopharmaceuticals/administration & dosage , Aged , Bone Neoplasms/secondary , Humans , Male , Maximum Tolerated Dose , Middle Aged , Organometallic Compounds/adverse effects , Organometallic Compounds/pharmacokinetics , Organophosphorus Compounds/adverse effects , Organophosphorus Compounds/pharmacokinetics , Palliative Care/methods , Prostatic Neoplasms/pathology , Radioisotopes/administration & dosage , Radioisotopes/adverse effects , Radioisotopes/pharmacokinetics , Radiometry , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/pharmacokinetics , Radiotherapy Dosage , Tissue DistributionABSTRACT
177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from bone pain due to metastatic skeletal carcinoma. The present article describes the evaluation of 177Lu-EDTMP complex in four different canine patients with different types of primary and metastatic skeletal lesions with respect to its pharmacokinetic properties, dosimetry and therapeutic efficacy. The dogs were treated with a dose of ~44.4 MBq (1.2 mCi) per kg body weight of 177Lu-EDTMP, synthesized in-house with high radiochemical purity (98.8 ± 0.4 %) and excellent in vitro stability. The radiopharmaceutical showed favourable pharmacokinetic properties, such as, preferential accumulation at skeletal lesion sites and fast clearance from blood and other non-target organs through urinary route. The administered dose of the radiopharmacutical showed excellent therapeutic efficacy in case of a dog suffering from skeletal metastasis originating from primary tumor elsewhere. On the other hand, two of the remaining three patients with primary bone cancer showed stable disease intially with palliative effect. The fourth patient having metal implant induced osteosarcoma with severe limb oedema did not show any response to the treatment.